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The ITEQ comprises 28 items with the subscales ‘leisure activi-
ties’ (4 items), ‘psychological barriers’ (2 items), ‘handling’ (5
items), ‘diabetes control’ (6 items), ‘dependence’ (5 items),
‘weight control’ (3 items), ‘sleep’ (2 items) as well as one item
assessing general TS. First results demonstrated good psychome-
tric properties. The aim of the present paper was to compare the
performance of the ITEQ and DTSQ in discriminating patients
TS in different insulin therapies. METHODS: A sample of
T2DM patients (n = 150) completed the ITEQ and DTSQ. TS as
assessed by the instruments was compared between respondents
with different insulin regimens (intensiﬁed insulin therapy,
n = 70; OAD plus insulin, n = 47; longacting insulin only, n = 33)
using analysis of variance (ANOVA). RESULTS: While ITEQ
subscales (diabetes control, dependence, weight control, sleep)
and the total score revealed signiﬁcant differences in patients TS
between therapy regimens (p < 0.001), results for the DTSQ
score were only marginally signiﬁcant (p = 0.154). Furthermore
different patterns for ITEQ subscales were observed even for
variants of insulin therapy within one type of regimen. CON-
CLUSION: Comparisons with an existing measurement suggest
that the ITEQ performs well in discriminating TS levels in
patients undergoing diabetes treatment. The content of the ITEQ
subscales provide important information about speciﬁc aspects
of patients TS in insulin treatment. In the near future, the ITEQ
will be translated into other languages.
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OBJECTIVES: As an aid to diabetes clinical care and research we
sought to develop a valid and reliable instrument: the Diabetes
Medication Satisfaction Tool (DMSAT) to measure patient sat-
isfaction with a broad spectrum of diabetes treatment regimens
in primary care. This was a cross-sectional survey study to
develop and test a self-report questionnaire on satisfaction with
diabetes medications. METHODS: Item content was obtained
from focus groups of patients attending community health
clinics, pre-tested in a sample of 55 patients with Type 2 diabetes,
and examined in a sample of 140 patients of a group family
practice with a diagnosis of diabetes and prescribed medical
therapy. Factor analysis and tests of subscale and total score
means across clinical groups were used to examine measurement
characteristics. RESULTS: Sixteen items were retained assessing
four distinct medication treatment experiences: ease and conve-
nience, lifestyle burdens, well-being, and medical control. Con-
struct validity of the scales and total score were demonstrated by
statistically signiﬁcant (p < 0.05) associations with treatment
complexity, follow-up visits, self-rated glucose control, health
worries, and A1c in the last six months. Internal consistency
reliability coefﬁcients for the scales and total score ranged from
0.89 to 0.95. CONCLUSION: The results of this study suggest
that the DMSAT has good construct validity and reliability, and
is sensitive to levels of clinical and patient reported outcomes that
relate to treatment burden and Type II diabetes control. The
DMSAT offers a comprehensive assessment of the patient accept-
ability and satisfaction with the use of diabetes medication
therapy in their daily life. Testing across two independent patient
samples showed DMSAT scores correspond to clinically relevant
outcomes.
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OBJECTIVES: To compare the number of steps, associated time
and costs related to administration of human growth hormone
(hGH) via different devices using time-and-motion simulations.
Previously all hGH formulations required reconstitution of lyo-
philized powder and transfer to syringe prior to administration.
With the development of a liquid formulation of hGH, premixed
and preﬁlled disposable devices are now available. Daily compli-
ance may depend upon “ease of use” characteristics across
various product and device combinations. Also, the additional
time required to prepare devices which are not available with
premixed product may result in increased costs from professional
and patient perspectives. METHODS: It is assumed the users
attend 1 training session, prepare 1 preparation per week, and
administer the drug three or seven times per week depending on
the product labeling speciﬁcations. This study simulates 3 phases:
Learning (initial instructions for use), Preparation (opening a
new package and making the device ready for use), and Admin-
istration (the actual injection of either the ﬁrst dose or subse-
quent doses). Nurses without prior experience with the
application of hGH or similar drug-device combinations are,
after the initial training session, running 5 series of preparations,
initial administrations, and follow-up dose administrations to
reﬂect the learning curves in the respective steps. Costs will
include wages (Bureau of Labor Statistics) and drugs (First Data-
bank). RESULTS: This study design provides a unique method to
compare the learning curves for the different product/device com-
binations, and to compare the relative time needed for prepara-
tion and administration. The validated methods and preliminary
results will be part of the presentation. CONCLUSION: This
time and motion study protocol, allows for comparing the
number of steps and the overall time required for preparation
and application of hGH in various devices and can be applied to
self injectable product comparisons in general.
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OBJECTIVES: Through a literature review, evaluate the inci-
dence rates of different adverse events associated with blood
transfusions among the general population. METHODS: A
structured, 2-phase literature review was conducted using the
PubMed (National Library of Medicine) database to search for
articles quoting incidence rates of adverse reactions associated
with blood transfusions. The ﬁrst phase of the literature review
looked for general blood transfusion risk studies reported during
the time period of 1985 to 2007 to identify adverse events
associated with blood transfusions. The second phase of the
literature review, looking at studies reported 2000 to 2007,
assessed incidence rates for each adverse event identiﬁed during
the ﬁrst phase. The search generated 41 articles from which data
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